Read by QxMD icon Read

Clinical Genitourinary Cancer

Kazutaka Okita, Shingo Hatakeyama, Toshiaki Tanaka, Yoshinori Ikehata, Toshikazu Tanaka, Naoki Fujita, Yusuke Ishibashi, Hayato Yamamoto, Takahiro Yoneyama, Yasuhiro Hashimoto, Kazuaki Yoshikawa, Toshiaki Kawaguchi, Naoya Masumori, Hiroshi Kitamura, Chikara Ohyama
PURPOSE: To investigate the impact of the risk group disagreement between the Memorial Sloan Kettering Cancer Center (MSKCC) and the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) models on prognosis. PATIENTS AND METHODS: We retrospectively evaluated 176 patients with metastatic renal-cell carcinoma who were treated with tyrosine kinase inhibitors as first-line therapy in 5 hospitals between October 2008 and August 2018. The risk group classification differences between the MSKCC and the IMDC models were evaluated using criteria of agreement (identical risk group in both the MSKCC and IMDC models) and disagreement (not identical risk group in both the MSKCC and IMDC models)...
January 17, 2019: Clinical Genitourinary Cancer
Jacob J Adashek, Meghan M Salgia, Edwin M Posadas, Robert A Figlin, Jun Gong
Renal-cell carcinoma remains one of the elusive cancers that lacks a biomarker. It is the eighth most commonly diagnosed malignancy in the United States, and the incidence has slowly trended upward. In addition to the increase in newly diagnosed cases, the prevalence and overall survival of individuals with kidney cancer also has increased substantially. This formal review synopsizes the literature regarding the current treatment landscape, the utility of biomarkers in renal-cell carcinoma, and future directions regarding next-generation sequencing of circulating tumor DNA...
January 15, 2019: Clinical Genitourinary Cancer
Wenbiao Ren, Bichen Xue, Minfeng Chen, Longfei Liu, Xiongbing Zu
INTRODUCTION: The study was carried out to examine the expression of ataxia telangiectasia mutant (ATM) of clear cell renal cell carcinoma (ccRCC), and to explore the relationship between the expression of ATM and the clinicopathologic parameters and prognosis of ccRCC. MATERIALS AND METHODS: Clinicopathologic data of the patients with ccRCC were collected from January 2011 to August 2015 in Xiangya Hospital, Central South University. The immunohistochemical method was used to detect the expression of ATM in ccRCC and adjacent tissues...
January 10, 2019: Clinical Genitourinary Cancer
Leah Rushin, Brian Reys, Yuval Freifeld, Matthew Karpowicz, David Fetzer, Aditya Bagrodia
No abstract text is available yet for this article.
January 10, 2019: Clinical Genitourinary Cancer
Sahyun Pak, Dalsan You, In Gab Jeong, Cheryn Song, Jae-Lyun Lee, Bumsik Hong, Jun Hyuk Hong, Choung-Soo Kim, Hanjong Ahn
BACKGROUND: The aim of this study was to compare survival outcomes in patients with clinically node-positive muscle-invasive bladder cancer receiving induction chemotherapy (IC) followed by surgery and those who underwent upfront radical cystectomy (RC). PATIENTS AND METHODS: Outcomes were reviewed in patients with cT2-4N1-3M0 bladder cancer treated with IC followed by surgery or upfront RC between January 1995 and June 2017. Survival outcomes were analyzed using a propensity score matched cohort analysis...
January 9, 2019: Clinical Genitourinary Cancer
Francesco Massari, Vincenzo Di Nunno, Veronica Mollica, Jeffrey Graham, Lidia Gatto, Daniel Heng
Although tyrosine kinase inhibitors (TKIs) are widely used in the metastatic setting, they have shown more limited effectiveness in the adjuvant setting. Despite multiple clinical trials, there has been no improvement in overall survival (OS) with the use of these agents as adjuvant therapy, and conflicting data on disease-free survival (DFS). We carried out a meta-analysis of available phase III randomized clinical trials on adjuvant TKIs in clear-cell renal cell carcinoma (RCC). Primary end points of our study were the effect of adjuvant TKIs on OS and DFS in the overall population...
January 4, 2019: Clinical Genitourinary Cancer
Omar Abdel-Rahman
BACKGROUND: The objective of the study was to evaluate the outcomes of clinically localized prostate cancer treated with prostatectomy versus radiation therapy within the context of a prospective prostate cancer screening study. PATIENTS AND METHODS: Within the PLCO (Prostate, Lung, Colorectal, and Ovary) trial, patients who were diagnosed with clinically localized prostate cancer and subsequently received treatment with prostatectomy or radiation therapy (with or without hormonal treatment) were included...
January 4, 2019: Clinical Genitourinary Cancer
Michael Mark, Dirk Klingbiel, Ulrich Mey, Ralph Winterhalder, Christian Rothermundt, Silke Gillessen, Roger von Moos, Michael Pollak, Gabriela Manetsch, Räto Strebel, Richard Cathomas
BACKGROUND: There is evidence linking metformin to improved prostate cancer-related outcomes. PATIENTS AND METHODS: Twenty-five men with metastatic castration-resistant prostate cancer and prostate-specific antigen (PSA) progression while receiving treatment with abiraterone from 3 Swiss centers were included in this single-arm phase 2 trial between November 2013 and September 2016. Metformin was added to abiraterone continuously at 1000 mg twice daily in uninterrupted 4-week cycles...
January 2, 2019: Clinical Genitourinary Cancer
Jost von Hardenberg, Sarah Hartmann, Katja Nitschke, Thomas Stefan Worst, Saskia Ting, Henning Reis, Philipp Nuhn, Cleo-Aron Weis, Philipp Erben
BACKGROUND: Prostate cancer with neuroendocrine differentiation (NEPCA) shares similarities in tumor biology with small-cell lung cancer. While immunotherapies were successfully tested in small-cell lung cancer, and programmed death ligand 1 (PD-L1) expression arises as an essential predictive biomarker, the local immune status in NEPCA is still poorly described. PATIENTS AND METHODS: Paraffin-embedded tissue samples of 39 patients (7 adenocarcinomas with neuroendocrine differentiation [ACA NED], 20 small-cell neuroendocrine carcinomas, 2 well-differentiated neuroendocrine tumors of NEPCA, and 10 adenocarcinoma liver metastases) were examined retrospectively by immunohistochemistry of chromogranin A (CGA), CD56, synaptophysin (SYN), CD3, and PD-L1...
December 21, 2018: Clinical Genitourinary Cancer
Erik Wibowo, Richard J Wassersug, John W Robinson, Andrew Matthew, Deborah McLeod, Lauren M Walker
BACKGROUND: Androgen deprivation therapy (ADT) for prostate cancer has numerous side effects. Clinical guidelines for side effect management exist; however, these are not always integrated into routine practice. What remains undocumented and therefore the objective of this study, is to describe patients' willingness to employ established strategies. PATIENTS AND METHODS: Study participants were 91 men who had attended an educational program (ie, attend a class plus read a book), designed to prepare patients for managing ADT side effects...
December 20, 2018: Clinical Genitourinary Cancer
Hang Huong Ling, Yung-Chang Lin
No abstract text is available yet for this article.
December 19, 2018: Clinical Genitourinary Cancer
Merel van Nuland, Steffie Groenland, Andre M Bergman, Joris I Rotmans, Hilde Rosing, Jos H Beijnen, Alwin D R Huitema
No abstract text is available yet for this article.
December 19, 2018: Clinical Genitourinary Cancer
Tejas Suresh, Janaki Sharma, Sanjay Goel, Evan Kovac, Qi Gao, Benjamin Gartrell
BACKGROUND: In the United States, the prostate cancer (PCa) incidence and death rate has been greater in non-Hispanic black (NHB) men than in non-Hispanic white (NHW) men and slightly lower in Hispanic men than in NHW men. We compared the sociodemographic and baseline prognostic factors at the diagnosis of PCa in different races/ethnicities at a large, academic center serving an ethnically diverse population. METHODS: The Montefiore Medical Center Cancer Registry was used to generate a comprehensive list of all patients with PCa diagnosed from 2004 to 2014...
December 13, 2018: Clinical Genitourinary Cancer
Alp Tuna Beksac, Mesude Bicak, Ishan Paranjpe, David J Paulucci, John P Sfakianos, Ketan K Badani
BACKGROUND: Chromophobe renal cell carcinoma (chRCC) is known as an indolent tumor; however, mortality still occurs. We sought to determine the clinicopathologic and genomic factors associated with aggressive chRCC. PATIENTS AND METHODS: Two different datasets were used to identify patients with clinical stage III and IV chRCC. Eighteen patients from The Cancer Genome Atlas (TCGA) database and 1693 patients from the American College of Surgeons National Cancer Database (NCDB) were used for analysis...
December 8, 2018: Clinical Genitourinary Cancer
Satoshi Noda, Tetsuya Yoshida, Daiki Hira, Ryosuke Murai, Keiji Tomita, Teruhiko Tsuru, Susumu Kageyama, Akihiro Kawauchi, Yoshito Ikeda, Shin-Ya Morita, Tomohiro Terada
BACKGROUND: Severe adverse events frequently occur in patients treated with pazopanib, necessitating dose reduction and discontinuation. However, information on the exposure-toxicity relationship is limited. PATIENTS AND METHODS: For this retrospective and observational clinical study, we examined 27 patients with renal cell carcinoma treated with pazopanib and enrolled between October 2014 and March 2018. The primary goal was to evaluate the association between trough pazopanib concentration and occurrence of grade ≥ 3 toxicities, and secondarily, to estimate the association between trough pazopanib concentration and objective response rate...
December 7, 2018: Clinical Genitourinary Cancer
Elie G Dib, Emmanuel S Antonarakis, Matthew J Wasco, Steven F Powell
No abstract text is available yet for this article.
December 6, 2018: Clinical Genitourinary Cancer
Elise Bonnet, Sophie Tartas, Anne Lazareth, Alexandre Jaouen, Blandine Tamarelle, Benoit You, Denis Maillet
No abstract text is available yet for this article.
December 5, 2018: Clinical Genitourinary Cancer
I Alex Bowman, Alisha Bent, Tri Le, Alana Christie, Zabi Wardak, Yull Arriaga, Kevin Courtney, Hans Hammers, Samuel Barnett, Bruce Mickey, Toral Patel, Tony Whitworth, Strahinja Stojadinovic, Raquibul Hannan, Lucien Nedzi, Robert Timmerman, James Brugarolas
BACKGROUND: Brain metastases (BM) occur frequently in patients with metastatic kidney cancer and are a significant source of morbidity and mortality. Although historically associated with a poor prognosis, survival outcomes for patients in the modern era are incompletely characterized. In particular, outcomes after adjusting for systemic therapy administration and International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk factors are not well-known. PATIENTS AND METHODS: A retrospective database of patients with metastatic renal cell carcinoma (RCC) treated at University of Texas Southwestern Medical Center between 2006 and 2015 was created...
December 5, 2018: Clinical Genitourinary Cancer
Anastasios Kyriazoglou, Michael Liontos, Costantinos Papadopoulos, Afroditi Bilali, Euthymios Kostouros, Stamatina Pagoni, Konstantinos Doumas, Meletios Athanasios Dimopoulos, Aristotelis Bamias
No abstract text is available yet for this article.
December 4, 2018: Clinical Genitourinary Cancer
William N Maish, Lan K Nguyen, Charles Ngu, Genevieve Bennett, Ganesalingam Pranavan
No abstract text is available yet for this article.
December 4, 2018: Clinical Genitourinary Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"